<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Commenti a: EHA25Virtual: Ruxolitinib, the First Proven Drug for Treating Steroid-refractory Acute GVHD 	</title>
	<atom:link href="https://www.newpharmaitaly.it/eha25virtual-ruxolitinib-the-first-proven-drug-for-treating-steroid-refractory-acute-gvhd/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.newpharmaitaly.it/eha25virtual-ruxolitinib-the-first-proven-drug-for-treating-steroid-refractory-acute-gvhd/</link>
	<description>Il portale delle news in ambito farmaceutico</description>
	<lastBuildDate>Fri, 12 Jun 2020 04:31:02 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.9.4</generator>
</channel>
</rss>
